The @theNCI #MyeloMATCH precision medicine trial for #AML or #MDS has some initial results that are being presented in an oral presentation and 5 posters at the #ASH25 meeting this weekend! Find out more here > buff.ly/6HaGwyz
@SWOG
@eaonc
@ALLIANCE_org
#NCORP
#CCTG trial spotlight for #LeukemiaAwarenessMonth & #ChildhoodCancerAwarenessMonth: The ALC6 study is testing if adding another drug to standard treatment improves outcomes for young adults with newly diagnosed B-cell acute lymphoblastic leukemia.
#myeloMATCH
Trial Info -> buff.ly/TZ0YRC0
#CCTG Trial Highlight for #LeukemiaAwarenessMonth : ALC8 is testing four innovative treatment combinations for newly diagnosed high-risk acute #myeloid #leukemia to find better first-line options for patients.
#myeloMATCH #SolvingCancerTogether
Trial info -> buff.ly/NLWIgT7
myeloMATCH substudy MM1OA-S03 is now open
#myeloMATCH is the NCI’s #PrecisionMedicine trial in #myeloid cancers. Substudy MM1OA-S03
enrolls patients who are age 60+ or unfit for chemo and have newly diagnosed AML with an
IDH2 gene mutation (~15% of pts).
swog.org/clinical-trials/MM1OA-S03 #leusm #leukemia @urochester.bsky.social
#CCTG has presented the Phase III Program Team Award for an intergroup led trial to the ALC.7 team from Arthur J.E. Child Comprehensive Cancer Centre for their performance on this #myeloMATCH protocol. #CCTG2025
myeloMATCH Precision Medicine in Myeloid Cancer
#myeloMATCH sub-study MM1OA-S03 is open!
Patients registered to MYELOMATCH screening protocol who are 60+ or unfit for chemo and have AML w an IDH2 gene mutation may be assigned. Randomized to venetoclax + ASTX727 w/wo enasidenib.
swog.org/clinical-trials/MM1OA-S03 @beatalleukemia.bsky.social
myeloMATCH: Precision medicine in myeloid cancer - AML - MDS
#myeloMATCH substudies treat patients with #AML or #MDS sequentially from diagnosis thru all treatment stages. After each treatment, patients are rescreened for assignment to a substudy in another tier. #NCI @eaonc.bsky.social @swog.org
swog.org/myeloMATCH-overview
The #CCTG ALC8 trial has opened, testing the effects of novel therapeutics for newly diagnosed, untreated acute myeloid leukemia #AML patients. This trial is part of the #myeloMATCH precision medicine protocol for #AML #MDS patients. #SolvingCancerTogether
https://buff.ly/419yN3S
myeloMATCH MM1YA-S01
#myeloMATCH MM1YA-S01 is enrolling adults ages 18-59 with newly diagnosed high-risk #AML.
Randomized 5-arm comparison of induction therapies. Primary endpoint: MRD-negative complete remission rate. swog.org/clinical-tri...
Co-PI: Tara Lin, MD #leusm #AMLsm #leukemia
Dr. Harry Erba interviewed by Society of Hematologic Oncology news on #myeloMATCH trial in AML & MDS: "It’s about creating a model for how we can use science, technology, and collaboration to revolutionize cancer care." @eaonc.bsky.social @dukemedschool.bsky.social
sohoinsider.com/leukemia/nci...
myeloMATCH sub-study MM1YA-S01
MM1YA-S01 is a randomized Tier-1 #myeloMATCH substudy comparing SOC cytarabine + danorubicin induction to 4 other induction therapies in adults <60 yrs w high-risk #AML.
SWOG.org/clinical-trials/MM1YA-S01 #leusm #AMLsm #leukemia
PI: Paul J. Shami, MD @huntsmancancer.bsky.social @mtmdphd.bsky.social
Advanced biomarker testing for adults with acute myeloid leukemia or myelodysplastic syndrome
#myeloMATCH is the NCI’s #precisionmedicine trial in #myeloid cancer: advanced biomarker testing in newly diagnosed acute myeloid #leukemia (#AML) or #myelodysplastic syndrome (#MDS) & treatment substudies by the Alliance, Canadian Cancer Trials Group, @eaonc.bsky.social & SWOG. swog.org/myeloMATCH
